UniSa - IRIS Institutional Research Information System

SABBATINO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.409
NA - Nord America 2.206
EU - Europa 1.428
SA - Sud America 232
AF - Africa 29
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.314
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 2.285
US - Stati Uniti d'America 2.167
SG - Singapore 523
IT - Italia 369
RU - Federazione Russa 281
DE - Germania 254
CN - Cina 233
BR - Brasile 219
VN - Vietnam 103
IE - Irlanda 99
FI - Finlandia 97
TR - Turchia 97
SE - Svezia 68
UA - Ucraina 65
KR - Corea 55
AT - Austria 51
IN - India 46
GB - Regno Unito 32
NL - Olanda 28
CA - Canada 24
CZ - Repubblica Ceca 24
FR - Francia 21
PL - Polonia 14
MX - Messico 10
ZA - Sudafrica 10
NP - Nepal 9
ES - Italia 8
JP - Giappone 8
UZ - Uzbekistan 8
IQ - Iraq 6
BD - Bangladesh 5
SA - Arabia Saudita 5
TH - Thailandia 5
AR - Argentina 4
AU - Australia 4
ID - Indonesia 4
MA - Marocco 4
NZ - Nuova Zelanda 4
PK - Pakistan 4
AL - Albania 3
DZ - Algeria 3
GR - Grecia 3
IR - Iran 3
KE - Kenya 3
LT - Lituania 3
TN - Tunisia 3
CH - Svizzera 2
EC - Ecuador 2
EG - Egitto 2
KG - Kirghizistan 2
MY - Malesia 2
SN - Senegal 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
GF - Guiana Francese 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
KI - Kiribati 1
ML - Mali 1
MM - Myanmar 1
NA - Namibia 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.314
Salva come PNG Salva come JPEG
Città #
Hong Kong 2.285
Ann Arbor 377
Chandler 304
Princeton 274
Munich 192
Singapore 192
Dallas 155
Ashburn 102
Dublin 94
Naples 92
Dong Ket 91
Izmir 91
Jacksonville 88
Moscow 72
Beijing 69
Wilmington 69
Andover 56
Pellezzano 52
Houston 48
Nuremberg 43
Helsinki 42
Los Angeles 38
Nanjing 32
Vienna 32
Salerno 31
Turku 31
Woodbridge 30
Boardman 27
Brno 23
Fairfield 19
The Dalles 19
Pune 17
Changsha 16
Nanchang 16
Norwalk 14
San Francisco 14
Warsaw 14
Columbus 13
Brooklyn 12
New York 12
Sarno 12
São Paulo 12
Fisciano 11
Lappeenranta 11
Paris 11
Seattle 11
Milan 10
Boston 9
Santa Clara 9
Amsterdam 8
Atlanta 8
Jiaxing 8
Kathmandu 8
San Diego 8
Shanghai 8
Belo Horizonte 7
Domicella 7
Orange 7
Rio de Janeiro 7
Shenyang 7
Toronto 7
Washington 7
Cambridge 6
Charlotte 6
Chennai 6
Hebei 6
Jyväskylä 6
Tashkent 6
Brasília 5
Chicago 5
Council Bluffs 5
Hanoi 5
Johannesburg 5
London 5
Manchester 5
Redwood City 5
Tokyo 5
Zhengzhou 5
Cellole 4
Chiang Mai 4
Dearborn 4
Jakarta 4
Mercato San Severino 4
Montreal 4
Mumbai 4
San Gennaro Vesuviano 4
Secaucus 4
Shijiazhuang 4
Stella Cilento 4
Tianjin 4
Auckland 3
Baghdad 3
Bologna 3
Carbonara di Nola 3
Delhi 3
Düsseldorf 3
Florence 3
Greenville 3
Guarulhos 3
Ho Chi Minh City 3
Totale 5.555
Salva come PNG Salva come JPEG
Nome #
Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors 393
KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies 380
Suitability of Different Cytological Preparations for Molecular Analysis of Advanced Non-Small Cell Lung Cancers 361
Cytopathological differential diagnosis of malignant tumor cells in the cerebrospinal fluid: A retrospective analysis 314
Natural Health Products for Anti-Cancer Treatment: Evidence and Controversy 300
Abstract 3132: Single nucleotide polymorphisms (SNPs) in PD-L1 as predictive biomarkers for checkpoint inhibitor based-immunotherapy in caucasian patients with advanced NSCLC 236
Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series 209
rs822336 as a predictive biomarker for anti-PD-1/PD-L1 immunotherapy in advanced NSCLC: Unraveling molecular mechanisms 130
Antitumor activity of BRAF inhibitor and IFN×alpha; Combination in BRAF-mutant melanoma 114
The Current and Future Impact of Lymph Node Fine-Needle Aspiration Cytology on Patient Care 112
Cell growth-inhibition and cell cycle perturbations induced by a new synthetic iminoquinone, 5H-pyridophenoxazin-5-one, in human breast carcinoma cell lines. 108
Inhibition of NF-kB activity potentiates ionizing radiation and cisplatin induced cell killing of anaplastic thyroid carcinoma cells AACR Meeting Abstracts, Apr 2006; 2006: 1038. 105
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers 104
The farnesyltransferase inhibitor R115777 (Zanestra) synergizes with ionizing radiation in inducing cell cycle perturbation and growth inhibition of human epidermoid head and neck cancer cells. 98
Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma 97
A genotyping/phenotyping approach with careful clinical monitoring to manage the fluoropyrimidines-based therapy: Clinical cases and systematic review of the literature 94
Counteracting resistance to treatments in solid tumors. 86
Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC 84
Abstract 3703: PDGFRα up-regulation mediated by Sonic Hedgehog Pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation 82
Abstracts of CIRSE (Cardiovascular and Interventional Radiological Society of Europe) 2011. September 10-14, 2011. Munich, Germany 82
Abstracts of CIRSE (Cardiovascular and Interventional Radiological Society of Europe) 2010. October 2-6, 2010. Valencia, Spain 78
Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors 78
Proceedings of the XXII National Conference of the Italian Society of Cytometry GIC, October 4–8, 2005, San Bendetto del Tronto (AP), Italy 77
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer 75
Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Case Report and a Narrative Review 73
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. 73
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase i inhibitor or radiation 72
Abstract 3639: Combinatorial therapy for triple negative breast cancer 72
597 IMPACT OF CONTRAST-ENHANCED ULTRASONOGRAPHY ON DIAGNOSTIC WORK-UP OF FOCAL LIVER ANOMALIES: EXPERIENCE IN A SINGLE HEPATOLOGY UNIT 69
Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells 67
Abstract 4741: Inhibition of TNBC cell growth by CSPG4-specific mAb 225.28 with a Sonic Hedgehog pathway inhibitor 66
Molecules and mechanisms to overcome oxidative stress inducing cardiovascular disease in cancer patients 66
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma 65
The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology 63
Blocking the formation of radiation-induced breast cancer stem cells 60
"Idealized" vs. "true" learning curves: The case of laparoscopic liver resection 60
Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma 59
Real-world experience with the Sydney System on 1458 cases of lymph node fine needle aspiration cytology 58
Multidisciplinary approach to patient with malignant melanoma 56
Epigenetic control of gene expression: Potential implications for cancer treatment 56
Variability in immune infiltrates and HLA expression in cholangiocarcinoma 55
Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches 54
Adverse events related to drug–drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review 54
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015 54
Ipilimumab in the treatment of metastatic melanoma: Management of adverse events 54
Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients 54
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells 51
PD-L1 Dysregulation in COVID-19 Patients 51
P.1.279: ADVANCED HCC ABLATION AFTER DOWSTAGING WITH SORAFENIB 50
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma 50
Identification of Drug Interaction Adverse Events in Patients with COVID-19: A Systematic Review 50
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC 49
Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma 49
Emerging BRAF inhibitors for melanoma 49
Combined fine needle aspiration cytology and core needle biopsy in the same setting: A two-years' experience 48
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature 48
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer 46
21st ISoP Annual Meeting “A New Era of Pharmacovigilance: Challenges and Opportunities” 20–23 September 2022 Verona, Italy 45
Ki67 in Gleason Pattern 3 as a Marker of the Presence of Higher-Grade Prostate Cancer 45
Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives 45
Diagnosis of Langerhans cell histiocytosis on cytological examination of cerebrospinal fluid: Report of the first case 44
Immune Checkpoint Inhibitors in Melanoma and HIV Infection 44
Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors 44
P.1.159: REPEATED LOCO-REGIONAL TREATMENTS: HIGH SURVIVAL RATES IN CIRRHOTIC PATIENTS WITH HEPATOCELLULAR CARCINOMA HIGHLY COMPLIANT TO SCHEDULED FOLLOW-UP 43
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation 43
Effect of tocilizumab in reducing the mortality rate in covid-19 patients: A systematic review with meta-analysis 43
Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice 42
Harnessing host innate immunity may combat acquired resistance to BRAFi 42
XXV Conferenza Nazionale di Citometria: INHIBITION OF POLY (ADP-RIBOSE) POLYMERASE SYNERGIZES WITH THE DNA-TOPOISOMERASE-1-INHIBITOR, TOPOTECAN, AND RADIATION IN HUMAN GLIOBLASTOMA CELL LINE 41
Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy? 41
PHH3 immunostaining: a novel prognostic biomarker in pancreatic neuroendocrine tumors 41
XXV Conferenza Nazionale di Citometria: CELL GROWTH INHIBITION AND CELL CYCLE PERTURBATIONS INDUCED BY A NEW SYNTHETIC IMINOQUINONE, 5H-PYRIDOPHENOXAZIN-5-ONE, IN HUMAN BREAST CARCINOMA CELL LINES 41
Genetic evolution of T-cell resistance in the course of melanoma progression 40
An economic evaluation of fine-needle cytology as the primary diagnostic tool in the diagnosis of lymphadenopathy 39
Testing egfr with idylla on cytological specimens of lung cancer: A review 38
A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram 37
P.1.112: IMPACT OF CONTRAST-ENHANCED ULTRASONOGRAPHY ON DIAGNOSTIC WORK-UP OF FOCAL LIVER ANOMALIES: EXPERIENCE IN A SINGLE HEPATOLOGY UNIT 37
Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study 36
Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors 36
Different Prognostic Role of Soluble PD-L1 in the Course of Severe and Non-Severe COVID-19 35
Clinical and Molecular Characteristics of Rare Malignant Tumors of Colon and Rectum 35
Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma 34
The ratio of grzb+ − foxp3+ over cd3+ t cells as a potential predictor of response to nivolumab in patients with metastatic melanoma 34
Cancer Cell Metabolism Reprogramming and Its Potential Implications on Therapy in Squamous Cell Carcinoma of the Head and Neck: A Review 33
Concomitant Administration of Capecitabine and Folate Supplements: Need to Encourage Medication Reconciliation 32
Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy 31
Immune checkpoint inhibitors for the treatment of melanoma 31
Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma 30
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence 30
PD-L1 and HLA class i antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma 29
Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy 29
The prognostic role of p53 mutations in metastatic colorectal cancer: A systematic review and meta-analysis 28
Melanoma initiating cells: where do we stand? 27
Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96 27
Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells 27
Novel combinatorial therapy for pancreatic adenocarcinoma 27
Advancing the integration of biosignal-based automated pain assessment methods into a comprehensive model for addressing cancer pain 27
Clinical and genetic drivers of oligo-metastatic disease in colon cancer 25
Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives 24
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors 23
Totale 7.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.843
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.843
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021216 0 7 13 7 10 19 21 3 7 1 20 108
2021/2022462 7 0 2 1 22 5 2 19 79 50 66 209
2022/2023752 77 80 68 128 55 144 1 48 98 1 42 10
2023/2024555 41 42 37 37 37 59 44 29 35 37 29 128
2024/20251.792 44 17 28 66 90 195 322 138 335 141 198 218
2025/20262.707 792 1.915 0 0 0 0 0 0 0 0 0 0
Totale 7.580